만성 기관지염 및 재발성 급성 호흡기감염 치료에 있어서 경구용 Biostim^(�)에 대한 임상 연구

장중현,이홍렬,장준,김성규 최신의학사 1992 最新醫學 Vol.35 No.7

죽재를 이용한 콘크리트의 사용성에 관한 실험적 연구

鄭熺孝,金洪俊,李承列,黃俊碩 경상대학교 생산기술연구소 2002 工學硏究院論文集 Vol.2 No.-

The purpose of this study is about the possibility of using bamboo to reinforce concrete in comparison with the reinforced concrete in the same experimental condition by conducting concrete using bamboo material and mechanical test of a bamboo. As a substitute material for the reinforced concrete, to check the possibility of using concrete with bamboo material either saving iron resources or developing lighter material was tried. Conclusions of this study can be summarized as follows; In contrast to reinforced concrete, bamboo concrete was failed brittly about cracked state, the failure was occurred by slip between concrete and bamboo before it reached yielding stress of bamboo. In the pullout test, bamboo pullout specimens were crushed by brittle crack and steel bar pullout specimens by pullout failure.

상자형의 전단지연 현상과 유효폭에 관한 연구

鄭熺孝,金洪俊,李承烈,朴峻熙 경상대학교 생산기술연구소 2002 工學硏究院論文集 Vol.2 No.-

In a box girder, it is an accepted practice in structural engineering to represent the effect of 'shear lag' by adopting an 'effective width' concept. The actual width of flange plate (b) is replaced by a reduced width (b_e) over which the longitudinal stresses may be considered uniformly distributed and the application of the elementary theory of bending to the transformed girder cross section gives the correct value of maximum longitudinal stress (σ_max). This paper provides how to determine the magnitude of 'shear lag' and 'effective width ratio' in case of orthotropic box girder which is simply supported, symmetrically loaded only.

Multiple Hypercoagulability Disorders at Presentation of Non-Small-Cell Lung Cancer

Lee, Jeong Min,Lim, Jun Hyeok,Kim, Jung-Soo,Park, Ji Sun,Memon, Azra,Lee, Seul-Ki,Nam, Hae-Seong,Cho, Jae-Hwa,Kwak, Seung-Min,Lee, Hong Lyeol,Kim, Hyun-Jung,Hong, Geun-Jeong,Ryu, Jeong-Seon The Korean Academy of Tuberculosis and Respiratory 2014 Tuberculosis and Respiratory Diseases Vol.77 No.1

Hypercoagulability disorders are commonly encountered in clinical situations in patients with a variety of cancers. However, several hypercoagulability disorders presenting as first symptoms or signs in cancer patients have rarely been reported. We herein described a case of a woman with adenocarcinoma of the lung presenting with deep vein thrombosis, nonbacterial thrombotic endocarditis, recurrent cerebral embolic infarction, and heart failure.

Case Reports : A Case of Pulmonary Inflammatory Pseudotumor: Recurrence Appearing as Several Consolidative Lesions after Complete Resection

Hong Lyeol Lee,Lu Cia Kim,Kyung Hee Lee,Kwang Ho Kim,Cheol Woo Kim 대한내과학회 2005 The Korean Journal of Internal Medicine Vol.20 No.2

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis

Lee, Sang Hoon,Yeo, Yoomi,Kim, Tae-Hyung,Lee, Hong Lyeol,Lee, Jin Hwa,Park, Yong Bum,Park, Jong Sun,Kim, Yee Hyung,Song, Jin Woo,Jhun, Byung Woo,Kim, Hyun Jung,Park, Jinkyeong,Uh, Soo-Taek,Kim, Young The Korean Academy of Tuberculosis and Respiratory 2019 Tuberculosis and Respiratory Diseases Vol.82 No.2

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for the treatment of patients with IPF through a systemic literature review using experts' help in conducting a meta-analysis. We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to facilitate the treatment of patients with IPF.

Implication of GAP model in idiopathic pulmonary fibrosis

( Lee Sang Hoon ),( Dong Soon Kim ),( Young Whan Kim ),( Man Pyo Chung ),( Soo Taek Uh ),( Choon Sik Park ),( Sung Hwan Jeong ),( Yong Bum Park ),( Hong Lyeol Lee ),( Jong Wook Shin ),( Eun Joo Lee ) 대한결핵 및 호흡기학회 2015 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.120 No.-

Background: Ley et al. demonstrated simple-to-use GAP model for predicting mortality in IPF patients. We investigated prognosis of IPF patients by each total GAP score. Method: The Korean Interstitial Lung Disease Study Group conducted a national survey to evaluate the clinical, physiological, radiological, and survival characteristics of IPF patients from January 1, 2003 to December 31, 2007. A total of 1,685 IPF patients were enrolled in this study. Among them, 1,262 patients performed pulmonary function test including DLco. Results: Patients were stratified into each total GAP score 0~7; GAP score 0 (n = 26); score 1 (n = 150), score 2 (n = 208); score 3 (n = 376); score 4 (n = 317); score 5 (n = 138); score 6 (n = 39); score 7 (n = 8). Patients with total GAP score zero, and seven were excluded in this analysis due to small number. Increased GAP score and advanced GAP stage were associated with a significantly poor prognosis (p < 0.001). In stage I, total GAP score 3 was significantly lower in survival than 1 or 2 groups (p = 0.027 and 0.022, respectively). Compared with stage II, survival of GAP score 3 was significantly superior than 4 or 5 groups (p = 0.025 and 0.001, respectively). Conclusion: Total GAP score 3 group showed significant difference comparing other score groups and showed eventually similar prognosis of patients with GAP stage II. This means that total GAP score 3 group should be divided from stage I group. Further large studies are needed to determine GAP stage divided with total GAP scores for predicting prognosis of IPF patients.

비소세포폐암에서 p53 종양억제 유전자와 K - ras 유전자의 돌연변이가 임상상에 미치는 영향

이홍렬(Hong Lyeol Lee),류정선(Jeong Seon Ryu),김주항(Joo Hang Kim),김성규(Sung Kyu Kim),이원영(Won Young Lee),이이형(Yi Hyung Lee) 대한내과학회 1998 대한내과학회지 Vol.55 No.5

N/A Objective: A multistep process of gene alterations is required for tumor formation, p53 gene mutation is the most frequent and K-ras gene mutation places second in the gene abnormalities of non-small cell lung cancer (NSCLC). The effect by the mutations of the p53 and ras genes on clinical manifestation is still highly controversial Little is known about the interaction between them in NSCLC. The present study was designed to investigate the effect by the mutations of the p53 tumor suppressor gene and K-ras oncogene on clinical manifestation, and the interaction between the mutations of two genes in the Korean NSCIC. Methods: Fifty-eight patients were enrolled in this study who had been diagnosed as having NSCLC from stage I to stage Ⅲ. They all had been alive for more than one month without any complication after curative resection. The paraffin-embedded lung tissues after resection were used to investigate the p53 expression by immunohistochemical staining, the mutations of the p53 and K-ras genes by polymerase chain reactionsingle strand conformation polymorphism(PCR-SSCP) and nucleotide sequencing. Results: p53 protein was overexpressed in 25.9% by immunohistochemical staining. Overexpression was significantly more frequent in epidermoid carcinoma(p=0.01634). But there was no significant difference between the overexpression group and the negative expression group according to stage and survival. By PCR-SSCP analysis, the mobility shift of the p53 gene was found in 29.1%. There was no significant difference between the groups with and without mobility shift according to cell type, stage and survival. By nucleotide sequencing, p53 gene mutation was 37.9%. The locations of mutation were dispersed among numerous codons and the modes of mutation were also diverse. There was also no significant difference between the groups with and without mutation according to cell type, stage and survival. K-ras gene mutation was 24.1% and only in codon 12 by nucleotide sequencing. Although there was no significant difference between the groups with and without mutation according to cell type or stage, K-ras gene mutation carried a significantly worse prognosis in NSCLC (overall survival p=0.0391, disease-free survival p=0.0318). When the patients were divided into 4 groups according to p53 gene mutation and K-ras gene mutation. there was also no significant difference among any group according to cell type or stage. The prognosis became worse if K-ras gene mutation accompanied(overall survival p=0.0021, disease-free survival p=0.0166). Only the stage(p=0.0313) and K-ras gene mutation(p=0.0457) were significant prognostic factors by Cox regression test. An analysis in stage III showed the significantly shorter survival period in the patients with K-ras gene mutation. K-ras gene mutation, therefore, was confirmed as the independently significant prognostic factor separately from stage. Conclusion: p53 gene mutation had no clinical or prognostic significance because of scattered locations and diverse modes of mutation in contrast to K-ras gene mutation, which had a significantly negative effect on the prognosis of NSCLC. p53 and K-ras gene mutations were apparently independent genetic alterations which played different roles in the clinical manifestation and prognosis of NSCLC.

기관지결석증에 대한 연구

이홍렬(Hong Lyeol Lee),김세규(Se Kyu Kim),장준(Joon Chang),김성규(Sung Kyu Kim),이원영(Won Young Lee),정경영(Kyong Young Chung) 대한내과학회 1995 대한내과학회지 Vol.48 No.3

N/A Objectives: Broncholithiasis is defined as a condition in which an concretion is present within a bronchus or a cavity in the lung communicating with a bronchus, It almost invariably represents the end stage of healing of granulomatous pulmonary diseases such as histioplasmosis or tuberculosis. Broncholiths are found with almost equal frequency in men and women, mostly in the fifth or sixth decade. Common symptoms are chronic cough, hemoptysis and sputum. Lithoptysis, which is pathognomic, is rare. The chest radiograph mostly shows calcified masses around the bronchi. In most cases, because of no significant symptoms or complication, observation may be the best course but bronchoscopic removal or surgical intervention are indicated in some instances. We report here the cases of broncholithiasis in which some clinical characteristics were observed. Methods: From January 1981 to December 1993, 13 patients with broncholithiasis had undergone the analysis for clinical manifestation, bronchoscopic fin- ding, treatment modality and follow-up status. Results : Broncholithiasis was distributed evenly from the fourth to the sixth decade and it developed in association with tuberculosis in 53.8%. Lithoptysis occurred in only 23.1% and calcification was found radiographically in 38.3%. Various positive findings, noted in all patients undergoing flexible bronchoscopy, included visualization of the broncholith, polypoid granulation tissue, stenotic or narrowed bronchi or blood clots. While 6 patients with conservative care only continued to have symptoms, an excellent result was evident in 3 of 7 patients in whom broncholith was removed after treatment or spontaneously. Conclusion: A clinical awareness of the manifestations of broncholithiasis will result in early diagnosis and treatment. As indicated, if the broncholith can be removed before irreversible distal bronchial and parenchymal damages occur, the long-term outlook for symptomatic relief is excellent.

폐외 악성 종양의 기관지내 전이

이홍렬(Hong Lyeol Lee),곽승민(Seung Min Kwak),장중현(Jung Hyun Chang),김세규(Se Kyu Kim),김성규(Sung Kyu Kim),이원영(Won Young Lee),신동환(Won Young Lee) 대한내과학회 1992 대한내과학회지 Vol.43 No.6

N/A Backgrounds: Endobronchial metastasis of extrapulmonary malignancies was defined as those cases in which metastatic foci were grossly evident in the main or lobar bronchi and occurs in less than 5% of all cases. The common extrapulmonary tumors associated with metastatic involvement of a central airway are carcinomas of the breast, kidney, colorectum and malignant melanoma. In the majority of cases, the primary tumor site is clinically apparent before symptoms of endobronchial metastasis. The clinical and roentgenographic features of endobronchial metastasis and primary bronchogenic carcinoma were found to be indistinguishable. Mostly, the histologic appearance of the bronchoscopic biopsy suggests the correct diagnosis but in some instances it may be impossible to differentiate metastatic involvement of the bronchus by an asymptomatic extrathoracic adenocarcinoma from a primary central adenocarcinoma of the lung. In addition to the treatment aspect of neoplasm spread, palliative surgical removal of endohronchial metastatic malignancies are strongly recommended to improve the patients qualify of life and to prevent resultant obstructive complications. Methods: We experienced 5cases of endobronchial metastasis during the recent 1½ years and reviewed the medical records of 12cases previously confirmed as endobronchial metastasis by bronchoscopic bioposies since 1985 to 1990. We investigated the clinical manifestations, primary sites, time intervals and bronchoscopic findings. Results: Breast carcinoma was the most common primary malignancy leading to the endobronchial metastasis. We also found the metastatic cases of hepatocellular carcinoma, sebacious gland adenocarcinoma and mouth floor carcinoma. Mostly patients complained of dyspnea and productive cough and chest X-ray revealed atelectasis. Endobronchial metastasis developed within 3 years in more than half of the cases and the mean time interval was 40,6months. In one prostate cancer and one thyroid cancer, metastasis was diagnosed prior to primary site presentation. On bronchoscopic examination, the right upper lobar bronchus was most commonly involved and subtotal obstruction was the most frequent finding. More than half of the patients expired within 2 years after the diagnosis of endobronchial metastasis. Conclusion: Endobronchial metastasis has unique clinical significance in that it requires differential diagnosis with primary bronchogenic carcinoma and aggressive palliative surgical management. If atypical clinical features are present or atypical cell type is discovered by biopsy of the lesion in lung ca, appropriate diagnostic studies should be undertaken to exlude the possibility of an asymptomatic extrapulmonary tumor before definite therapy is undertaken.